Zaharaddeen Umar Na’abba and Abhishek Kumar Verma*
Department of Life Sciences, School of Science and Technology, Mewar University, Gangrar, Chittorgarh Rajasthan, India
*Corresponding Author: Abhishek Kumar Verma, Assistant Professor, Department of Life Sciences, School of Science and Technology, Mewar University, Gangrar, Chittorgarh, Rajasthan, India. E-mail: abhishekbairwa913@gmail.com
Received: July 26, 2020; Published: August 01, 2020
Currently, the FDA for the treatment of COVID-19 pneumonia has approved no drugs or therapeutics vaccines. Some pharmacological treatment has gained emergency use authorization from FDA based on preliminary data displaying a faster time to recovery of hospitalized patients with severe COVID-19 infection. In this editorial, different pharmacological treatment that have been adopted for the management and treatment of COVID-19 pneumonia.
Citation: Zaharaddeen Umar Na’abba and Abhishek Kumar Verma. “Pharmacological Treatments and Development of SARS-CoV-2". Acta Scientific Pharmaceutical Sciences 4.9 (2020): 01-02.
Copyright: © 2020 Zaharaddeen Umar Na’abba and Abhishek Kumar Verma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
+91 9182824667
Open Access by
Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com
ff
